The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Is there promise for fixed-duration BTK and BCL2 inhibitor combination therapy in R/R CLL?
Paolo Ghia, MD, of Vita-Salute San Raffaele University, Milan, Italy, discusses the promise of fixed-duration BTK and BCL2 inhibitor combination therapy in chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting. Dr Ghia highlights that this combination therapy provides a potential retreatment option for patients who have progressed after initial treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes indeed that’s a trend that is occurring already since a few years and with the combination of BTK inhibitors and BCL2 inhibitors and at this meeting this year we do see the use of this combination also in the relapsed/refractory setting which is important because now we have treatments that are approved and used in clinical practice in frontline, but then the whole idea of a fixed-duration treatment is based on the fact that the patient can be retreated at the time of progression, and it is not at the moment possible...
Yes indeed that’s a trend that is occurring already since a few years and with the combination of BTK inhibitors and BCL2 inhibitors and at this meeting this year we do see the use of this combination also in the relapsed/refractory setting which is important because now we have treatments that are approved and used in clinical practice in frontline, but then the whole idea of a fixed-duration treatment is based on the fact that the patient can be retreated at the time of progression, and it is not at the moment possible. So we are very happy to see results from studies in the relapsed/refractory setting, again showing the feasibility and efficacy also of this combination in the secondary treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
